The HALT Biomarker Study

Summary

The HALT Biomarker Study is a clinical trial^[1].

Key Facts

• The HALT Biomarker Study is in the country of United States^[2].
• The HALT Biomarker Study's instance of is recorded as clinical trial^[3].
• The HALT Biomarker Study's start time is recorded as +2020-06-22T00:00:00Z^[4].
• The HALT Biomarker Study's end time is recorded as +2030-06-22T00:00:00Z^[5].
• The HALT Biomarker Study's sponsor is recorded as Massachusetts General Hospital^[6].
• The HALT Biomarker Study's main subject is recorded as aortic valve stenosis^[7].
• The HALT Biomarker Study's number of participants is recorded as {'unit': '1', 'amount': '+300'}^[8].
• The HALT Biomarker Study's title is recorded as Circulating Biomarkers of Hypo-Attenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement^[9].
• The HALT Biomarker Study's short name is recorded as HALT^[10].
• The HALT Biomarker Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[11].
• The HALT Biomarker Study's ClinicalTrials.gov ID is recorded as NCT04552275^[12].
• The HALT Biomarker Study's clinical trial phase is recorded as phase I clinical trial^[13].
• The HALT Biomarker Study's research site is recorded as Massachusetts General Hospital^[14].
• The HALT Biomarker Study's research subject recruitment status is recorded as recruiting^[15].
• The HALT Biomarker Study's study type is recorded as interventional study^[16].